Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
RIO
-0.3300
The Fort Worth Press - Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
USD
-
AED 3.673042
AFN 65.000368
ALL 81.855041
AMD 360.540403
ANG 1.790403
AOA 918.000367
ARS 1546.131265
AUD 1.476887
AWG 1.8
AZN 1.70397
BAM 1.769883
BBD 2.014669
BDT 124.411223
BGN 1.77347
BHD 0.37715
BIF 3005
BMD 1
BND 1.287984
BOB 11.678099
BRL 5.666304
BSD 1.000231
BTN 94.214794
BWP 13.981141
BYN 2.99667
BYR 19600
BZD 2.011773
CAD 1.42715
CDF 2315.000362
CHF 0.838719
CLF 0.025287
CLP 995.220396
CNY 6.67175
CNH 6.67522
COP 3319.97
CRC 448.217041
CUC 1
CUP 24.005936
CVE 100.150394
CZK 22.139304
DJF 177.720393
DKK 6.782304
DOP 60.703884
DZD 137.227489
EGP 53.502064
ERN 15
ETB 161.050392
EUR 0.90715
FJD 2.25325
FKP 0.756884
GBP 0.75683
GEL 2.590391
GGP 0.756884
GHS 11.72504
GIP 0.756884
GMD 74.000355
GNF 8857.503848
GTQ 7.646644
GYD 209.264655
HKD 7.84565
HNL 26.950388
HRK 6.831965
HTG 131.169348
HUF 331.003504
IDR 18235.4
ILS 3.216704
IMP 0.756884
INR 94.25795
IQD 1514
IRR 1913737.503816
ISK 123.930386
JEP 0.756884
JMD 158.047862
JOD 0.70904
JPY 159.72504
KES 130.050385
KGS 87.435504
KHR 4080.00035
KMF 447.00035
KPW 900.00035
KRW 1336.565039
KWD 0.31147
KYD 0.833529
KZT 445.849094
LAK 22530.000349
LBP 89550.000349
LKR 332.687818
LRD 170.000348
LSL 16.930381
LTL 2.95274
LVL 0.60489
LYD 6.445039
MAD 9.961704
MDL 18.169149
MGA 4590.000347
MKD 55.830725
MMK 2099.848767
MNT 3604.365716
MOP 8.083632
MRU 40.603743
MUR 47.620378
MVR 15.403739
MWK 1736.000345
MXN 18.536504
MYR 4.086104
MZN 63.903729
NAD 16.930377
NGN 1343.570377
NIO 36.803722
NOK 9.57248
NPR 150.739077
NZD 1.809628
OMR 0.385141
PAB 1.000231
PEN 3.403039
PGK 4.511504
PHP 63.960375
PKR 276.603701
PLN 3.996535
PYG 6207.891986
QAR 3.64425
RON 4.851904
RSD 106.559038
RUB 82.829047
RWF 1476
SAR 3.77446
SBD 8.097697
SCR 13.945304
SDG 601.503676
SEK 10.075038
SGD 1.287204
SHP 0.752984
SLE 23.050371
SLL 20969.503664
SOS 572.503662
SRD 37.49037
STD 20697.981008
STN 22.2
SVC 8.752585
SYP 13002.000337
SZL 16.930369
THB 33.875038
TJS 9.227282
TMT 3.5
TND 3.008504
TOP 2.40776
TRY 50.342104
TTD 6.789769
TWD 32.891404
TZS 2648.920367
UAH 45.477786
UGX 4131.053487
UYU 40.541335
UZS 12039.000334
VES 912.87925
VND 25725.5
VUV 120.638016
WST 2.81058
XAF 595.051667
XAG 0.020459
XAU 0.00025782798
XCD 2.70255
XCG 1.802699
XDR 0.707052
XOF 595.051667
XPF 108.325037
YER 236.550363
ZAR 16.976255
ZMK 9001.203584
ZMW 20.450473
ZWL 321.999592
SSP 5946.454122
MXV 2.081672
- Egypt's GAFI Wins WAIPA Awards for Investor Portal and Renewable Energy Project
- Canva Craft vs ChatGPT: Head-to-Head AI Image Generation Test
- BingX: Major Announcement of Far-Reaching Significance
- 2027 Rivian R2 Performance vs. 2026 Jeep Recon Moab: EV Comparison Test
- Anonymous Staff Letters Emerge at Surrey City Hall Amid Executive Absences
- Qatar and Turkey Sign Joint Defence Agreement in Istanbul
- New to The Street Show #780 Premieres Tonight on Bloomberg Television with Robo.ai, American Fusion, Stewards Investment Capital and FreeCast
- AI Unlocks Hundreds of Proved Theorems in Kurt Gödel’s Hidden Notebooks
- Rod Wave Files Motion to Suppress Evidence From April 2025 Vehicle Search
- SF Opera’s Energetic ‘Marriage of Figaro’ Cranks Volume to Eleven
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft (PDX) models.
"This license marks a significant milestone in our capability to support biopharmaceutical partners in developing next-generation radiotherapeutics," stated Ronnie Morris, CEO of Champions Oncology. "By integrating this expertise with our well-characterized PDX platform, we are uniquely positioned to drive the advancement of radiopharmaceutical development with unparalleled translational precision."
This comprehensive program will support drug developers across a range of modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.
For partnership inquiries or to learn more, please contact us at https://www.championsoncology.com/contact-us.
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
[email protected]
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
G.Dominguez--TFWP
